Finance Bill 2026: What the R&D Tax Credit and Knowledge Development Box changes mean for Irish businesses

The publication of Finance (No. 2) Bill 2026 provides further detail on the enhancements to Ireland’s R&D Tax Credit and Knowledge Development Box (KDB) announced in Budget 2027. The proposals include additional support for R&D employment, greater flexibility around subcontracted research, improved cash-flow arrangements and a five-year extension to the KDB regime.

The Finance Bill builds on the increase in the R&D Tax Credit rate from 30% to 35%, introduced by Finance Act 2025, which generally applies to accounting periods beginning on or after the 1st January 2026. While the Bill has yet to complete its passage through the Oireachtas, it provides a clearer picture of how the latest measures will operate and which businesses could benefit.

A new enhancement for R&D wage costs: The 5% Payroll Uplift

This proposal introduces a 5% artificial top-up on eligible R&D staff wages when calculating your R&D Tax Credit. Effectively, every €100 spent on research payroll is treated as €105 in qualifying expenditure.

The mechanism is designed to indirectly compensate companies for general business overheads that support R&D activity but are typically excluded from direct claims.

How It Works in Practice

• Standard Rule: If you pay a research engineer €100,000, your eligible claimable expense is exactly €100,000. (employee-cost simplification introduced by Finance Act 2025)

• Proposed Rule: You can claim €105,000 for that same engineer. Given Ireland’s 35% R&D tax credit rate, this 5% uplift directly increases your cash-back benefit.

Eligibility Criteria

To qualify for this bonus, your business must demonstrate that it incurs regular supporting overheads that do not otherwise qualify for the standard R&D credit.

• Examples of qualifying overheads: Office Rent, HR costs, or standard business software.

• Minimum threshold: This supporting spend must equal at least 5% of your total R&D payroll.

Greater flexibility for subcontracted R&D

The limits on qualifying R&D subcontracted to unconnected third parties and eligible third-level institutions will increase from the greater of 15% of qualifying non-outsourced R&D expenditure or €100,000 to the greater of 20% or €200,000.

This recognises the collaborative nature of modern R&D, where businesses frequently rely on specialist contractors, universities and external research facilities.

Improved cash flow and preliminary tax treatment

The first-instalment payment threshold will increase from €87,500 to €105,000, allowing companies with R&D Tax Credit claims of up to €105,000 to receive the full credit in the first instalment. Claims between €105,000 and €210,000 would receive more than half their value upfront.

The Bill also proposes extending the recognition of R&D Tax Credit instalments for preliminary corporation tax purposes. Currently, the first instalment can be recognised, subject to the relevant conditions and election. The proposed change would extend this treatment to second and third instalments carried forward from earlier claim periods.

Neither measure increases the overall value of a claim, but both could improve cash-flow planning, particularly for smaller businesses and companies with outstanding R&D Tax Credit instalments.

Regulated clinical trials: legislation still to come

The Budget 2027 proposal to allow the regulated status of a clinical trial to satisfy the science test for R&D Tax Credit purposes has not yet been included in the published Bill.

The measure could reduce the administrative burden for pharmaceutical, biotechnology and other life sciences businesses, including Irish companies contributing to global clinical trials. Further legislation is expected during Committee Stage, so the precise scope and operation remain to be confirmed.

Knowledge Development Box: extension and new exit provisions

The Finance Bill proposes extending the Knowledge Development Box for a further five years, making it available for accounting periods commencing before 1 January 2032. The KDB provides an effective 10% corporation tax rate on qualifying profits from eligible intellectual property developed through R&D.

The extension provides greater certainty for businesses developing and commercialising IP in Ireland, particularly where significant time may pass between undertaking R&D and generating commercial returns.

When will the changes take effect?

The main R&D Tax Credit enhancements proposed in Finance (No. 2) Bill 2026 are expected to apply to accounting periods beginning on or after the 1st January 2027. This is a year later than the increase to the 35% credit rate, which generally applies to periods beginning on or after the 1st January 2026. The KDB provisions have separate commencement arrangements, while the clinical trials measure remains subject to further legislation.

What should businesses consider?

The Finance Bill provides an opportunity for companies to review their R&D expenditure and assess how the proposed changes could affect future claims. Businesses with substantial R&D payroll costs or significant expenditure on external research partners may see additional benefits, while the revised payment and preliminary tax arrangements could improve cash flow.

For companies developing commercially valuable intellectual property, the KDB extension provides longer-term certainty. Existing claimants, particularly multinational groups, should also consider whether the proposed exit provisions have implications for their tax position.

The legislation is not yet final, but the direction is clear. Having increased the headline R&D Tax Credit rate, Ireland is now proposing changes that address how businesses undertake R&D, access financial support and commercialise the intellectual property it creates.

This article is based on Finance (No. 2) Bill 2026 as published in October 2026. The measures remain subject to amendment and enactment.